A research team has developed a multi-medium approach (MMA) to identify reproducible volatile organic compounds (VOCs) in ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in ...

A phase III study of combination therapy with everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor (JCOG1901, STARTER-NET) ...

This combination has “the potential to become a new standard first-line treatment” for well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors with poor prognostic factors ...

Comparative outcomes of neuroendocrine tumors in the historically underserved population of Bronx, NY: Montefiore Einstein Comprehensive Cancer Center. Pamrevlumab ...

Chemotherapy for lung cancer is used for different purposes depending on the type and stage of cancer you have. This includes achieving cancer remission, shrinking a tumor before surgery, killing ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...

This combination showed promising results in topically accessible tumors like melanoma and breast cancer models: The therapy led to the death of tumor cells at the treated sites and simultaneously ...

higher-numbered stages indicate the cancer has spread further and tumors are larger. Symptoms and treatment options depend on the stage of your lung cancer along with what type of NSCLC you're ...

Patients with functional neuroendocrine tumors may experience hormone-related syndromes, such as carcinoid syndrome ... Risk factors for pancreas and lung neuroendocrine neoplasms: A case-control ...

To understand these complex interactions, we measure the density of different cell types in the stroma using immunohistochemistry techniques on tumor samples from lung cancer patients. We incorporate ...